Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database

26 Sept 2022

Abstract excerpt

The outcomes and best treatment strategies for germline BRCA1/2 mutation (gBRCAm) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with a gBRCAm identified at initiation of first-line treatment with those of BRCA wild-type (WT) and not-tested (NT) individuals in the ESME real-world database of MBC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36161271
DOI: 10.1002/ijc.34304

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world databasePMID 36161271Read ↗

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Semantic proximity Read ↗

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.Semantic proximity Read ↗

Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.Semantic proximity Read ↗

Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution.Semantic proximity Read ↗

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world StudySemantic proximity Read ↗

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center ExperienceSemantic proximity Read ↗

Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.Semantic proximity Read ↗

Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA StatusSemantic proximity Read ↗

Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutationsSemantic proximity Read ↗

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.Semantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.